Literature DB >> 18216775

Ultra-low-dose naloxone restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in PTX-treated rats.

Ru-Yin Tsai1, Fong-Lin Jang, Yueh-Hua Tai, Shinn-Long Lin, Ching-Hui Shen, Chih-Shung Wong.   

Abstract

The aim of the present study was to examine the effect of ultra-low-dose naloxone on pertussis toxin (PTX)-induced thermal hyperalgesia in rats and its underlying mechanisms. Male Wistar rats, implanted with an intrathecal catheter with or without a microdialysis probe, received a single intrathecal injection of PTX (1 microg in 5 microl saline). Four days after PTX injection, they were randomly given a different dose of naloxone (either 15 microg or 15 ng in 5 microl saline), followed by a morphine injection (10 microg in 5 microl saline) after 30 min. The results found that PTX injection induced thermal hyperalgesia and increasing excitatory amino acid (EAA; L-glutamate and L-aspartate) concentration in the spinal CSF dialysates. Ultra-low-dose naloxone not only preserved the antinociceptive effect of morphine but also suppressed the PTX-evoked EAA release as well. Moreover, ultra-low-dose naloxone plus morphine administration inhibited the downregulation of L-glutamate transporters (GTs) and the L-glutamate-metabolizing enzyme glutamine synthetase (GS), and, moreover, inhibited microglial activation and suppressed cytokine expression in PTX-treated rat spinal cords. These results show that ultra-low-dose naloxone preserves the antinociceptive effect of morphine in PTX-treated rats. The mechanisms include (a) inhibition of pro-inflammatory cytokine expression, (b) attenuation of PTX-evoked EAA release, and (c) reversion of the downregulation of GT expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18216775     DOI: 10.1038/sj.npp.1301672

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  11 in total

Review 1.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.

Authors:  Linda R Watkins; Mark R Hutchinson; Kenner C Rice; Steven F Maier
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

Review 2.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

3.  Neonatal morphine administration leads to changes in hippocampal BDNF levels and antioxidant enzyme activity in the adult life of rats.

Authors:  J R Rozisky; G Laste; I C de Macedo; V S Santos; R Krolow; C Noschang; C Vanzella; K Bertoldi; G A Lovatel; I C C de Souza; I R Siqueira; C Dalmaz; W Caumo; I L S Torres
Journal:  Neurochem Res       Date:  2012-12-09       Impact factor: 3.996

4.  Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study.

Authors:  Jarred Younger; Sean Mackey
Journal:  Pain Med       Date:  2009-04-22       Impact factor: 3.750

5.  Effects of combined opioids on pain and mood in mammals.

Authors:  Richard H Rech; David J Mokler; Shannon L Briggs
Journal:  Pain Res Treat       Date:  2012-03-21

6.  Efficacy of an intrathecal multidrug infusion for pain control in older adults and in end-stage malignancies: A report of three cases.

Authors:  Sadegh Abdolmohammadi; Pierre-Olivier Hétu; Andrée Néron; Gilbert Blaise
Journal:  Pain Res Manag       Date:  2015 May-Jun       Impact factor: 3.037

Review 7.  Immune System Involvement in Specific Pain Conditions.

Authors:  Stacie K Totsch; Robert Ernest Sorge
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

Review 8.  Targeting Cytokines for Morphine Tolerance: A Narrative Review.

Authors:  Dai-Qiang Liu; Ya-Qun Zhou; Feng Gao
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

9.  A Low Dose of Naloxone Added to Ropivacaine Prolongs Femoral Nerve Blockade: A Randomized Clinical Trial.

Authors:  Seung Cheol Lee; Jeong Ho Kim; So Ron Choi; Sang Yoong Park
Journal:  Pain Res Manag       Date:  2021-01-31       Impact factor: 3.037

10.  Intrathecal gabapentin increases interleukin-10 expression and inhibits pro-inflammatory cytokine in a rat model of neuropathic pain.

Authors:  Byung-Sang Lee; In-Gu Jun; Sung-Hoon Kim; Jong Yeon Park
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.